A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis☆,☆☆,★
Section snippets
THE NEWER INTRANASAL STEROIDS: PRECLINICAL DATA
The anti-inflammatory effects of glucocorticoids are specific receptor-mediated actions inherently dependent on the binding of the steroid drug with intracellular glucocorticoid receptors (GR) and subsequent transcriptional activation leading to target-gene expression. The effects of glucocorticoids are thus dependent on their respective receptor-binding affinities and postbinding transcriptional activities. These parameters can be studied in vitro, and the relative in vivo potencies of agents
THE NEWER INTRANASAL STEROIDS: CLINICAL DATA
The actions of intranasal steroids seen in preclinical studies clarified somewhat the utility and mechanism of action of these agents in allergic inflammatory diseases. The in vitro tests were also a useful means of predicting and comparing the actions of the many drugs in this class. However, various other factors, such as metabolism, systemic availabilities, and formulation effects, may alter the predicted rank order of potencies in vivo. Allergen challenge tests and clinical trials with
CORTICOSTEROID SELECTION: PHARMACOKINETIC AND PHARMACODYNAMIC BEARINGS
It is clear from the preceding sections that topical glucocorticoids act by specific receptors to inhibit various inflammatory actions in both the immediate and subsequent time points after allergen exposure. Although the anti-inflammatory actions of these agents have been graded in vitro and confirmed in various clinical assays, in the final analysis agent efficacy, potency, usage, and compliance will depend on several factors, including the onset of action, ratio of systemic to local effects,
CONCLUSION
The development of new intranasal steroids has been based on scientific reasoning and chemical reconfiguration. Thus newer corticosteroids are more lipophilic, have greater affinities for GRs, and are more readily and completely metabolized by the liver, allowing for quick-acting drugs with generally localized actions and rapid elimination. Here we have compared the most commonly used intranasal corticosteroid agents through a review of their preclinical and clinical testing data (Table IV).1, 3
References (44)
Development of fluticasone propionate and comparison with other inhaled corticosteroids
J Allergy Clin Immunol
(1998)- et al.
The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon production by cultured primary CD4+ T cells
J Allergy Clin Immunol
(1997) - et al.
Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray
J Allergy Clin Immunol
(1998) Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis
Clin Ther
(1996)- et al.
A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray
J Allergy Clin Immunol
(1996) - et al.
Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients
Ann Allergy Asthma Immunol
(1996) - et al.
Lack of systemic activity with intranasal mometasone furoate
J Allergy Clin Immunol
(1996) - et al.
Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children
Clin Ther
(1997) - et al.
Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal axis activity
J Allergy Clin Immunol
(1998) - et al.
Once daily intranasal fluticasone propionate (200 mg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis
J Allergy Clin Immunol
(1996)
Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex™) in the treatment of perennial rhinitis
Otolaryngol Head Neck Surg
In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids
Arzneim Forsch Drug Res
In vitro and ex vivo binding to uterine progestin receptors of the rat as a tool to assay progestational activity of glucocorticoids
Methods Find Exp Clin Pharmacol
Local corticosteroid treatment: the effect on cells and cytokines in nasal allergic inflammation
Am J Rhinol
The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids
Allergy
Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy
Allergy
Immunologic effects of intranasal corticosteroids
Allergy Asthma Proc
Cytokine inhibition by a novel steroid, mometasone furoate
Immunopharmacol Immunotoxicol
The effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis (SAR)
Ann Allergy Asthma Immunol
Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids
N Engl J Med
Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid
Am J Respir Crit Care Med
Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis
Immunology
Cited by (77)
Mucoadhesive dexamethasone-glycol chitosan nanoparticles for ophthalmic drug delivery
2020, International Journal of PharmaceuticsCitation Excerpt :Dexamethasone (Dex) is one of the most widely used steroidal agents for the treatment of various inflammatory disorders with high potency and effectiveness (Lumry, 1999; De Gans and Van de Beek, 2002; De Bosscher et al., 2010).
Efficacy of the novel nasal steroid S0597 tested in an environmental exposure unit
2016, Annals of Allergy, Asthma and ImmunologyEfficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis
2015, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :Intranasal glucocorticosteroids (INSs) are regarded as the most effective pharmacologic treatment for AR and are recommended by the Allergic Rhinitis and its Impact on Asthma guidelines as first-line treatment.2,3 INSs have a good safety profile, with a low risk of systemic side effects owing to their low systemic bioavailability.4 This is especially true for newer INSs, such as ciclesonide, mometasone furoate, and fluticasone furoate, which have a systemic bioavailability lower than 1%.5
Inhaled corticosteroids and growth: Still an issue after all these years
2015, Journal of PediatricsSteroid treatment of eosinophilic esophagitis in adults
2014, Gastroenterology Clinics of North AmericaCitation Excerpt :The most commonly used drugs in clinical practice are fluticasone and budesonide. Both fluticasone and budesonide are highly potent topical steroids with affinity for binding to the glucocorticoid receptor several hundred times that of dexamethasone.11 The affinity of fluticasone is about threefold greater than budesonide.
- ☆
Supported by an unrestricted educational grant from Schering/Key Pharmaceuticals, Schering Corporation.
- ☆☆
Reprint requests: William R. Lumry, MD, American Board of Allergy and Immunology, 9900 N Central, Suite 525, Dallas, TX 75231.
- ★
0091-6749/99 $8.00 + 0 1/0/101681